Inhibitors of peptide binding to MHC class II proteins
US6184207A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 14, 1999 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Jun 14, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns pharmacologically useful peptide derivatives of the formula (I): P-AA.sup.1 -AA.sup.2 -AA.sup.3 -AA.sup.4 -AA.sup.5 -AA.sup.6 -AA.sup.7 -AA.sup.8 -Q, and pharmaceutically acceptable salts thereof, wherein either AA.sup.3 together with AA.sup.4, or AA.sup.4 together with AA.sup.5, or AA.sup.6 together with AA.sup.7 form a group of formula (II): ##STR1## in which Ra is selected from hydrogen and (1-4C)alkyl, and the remainder of AA.sup.1, AA.sup.2, AA.sup.3, AA.sup.4, AA.sup.5, AA.sup.6, AA.sup.7, and AA.sup.8 are L-amino acid residues; P is a hydrophobic residue; and Q is OH, NH.sub.2 or NRcRd. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds, and pharmaceutical compositions containing them, in treating MHC class II dependent T-cell mediated autoimmllne or inflammatory diseases, such as rheumatoid arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.